VENTURE
Y-Trap (Private)
Y-Trap Enters Collaboration with Merck KGaA, Darmstadt, Germany, to Develop Novel Antibody-Ligand Traps for Immuno-Oncology
Developer of technologies for cancer immunotherapy intended to bring revolutionary treatment procedure. The company's patended technology is a novel platform of targeted multi functional immunomodulatory antibody-ligand traps for cancer immunotherapy, enabling physicians avail targeted immunotherapeutic strategy for many types of advanced and treatment-refractory cancers that evade current monoclonal antibodies and immune checkpoint inhibitors.